HX08 From ‘children who burn in sunlight’ to DNA repair defect: xeroderma pigmentosum and the birth of molecular dermatology

Abstract

In the late nineteenth century, Hebra and Kaposi described children whose skin developed severe pigmentation, scarring and ulceration after minimal exposure to sunlight. These patients frequently developed multiple skin cancers in early childhood and often died young. The condition, later termed xeroderma pigmentosum (XP), was clinically recognizable but biologically unexplained. For much of the early 20th century, XP was managed as an extreme photosensitivity disorder. Treatment consisted almost entirely of avoidance: strict sun protection, protective clothing and social isolation. Care focused on shielding patients from injury rather than understanding the mechanism. As later commentators noted, management relied on environmental restriction rather than biological explanation. A fundamental shift occurred in 1968, when Cleaver demonstrated that cells from patients with XP were unable to repair ultraviolet-induced DNA damage. This discovery established XP as the first human disease directly linked to a defect in DNA repair. The skin was no longer viewed as unusually sensitive; it was genetically incapable of correcting environmental injury. With this finding, dermatology entered the molecular era. The implications extended far beyond a rare genodermatosis. XP provided direct evidence that cancer could result from failure of genomic maintenance. DNA repair disorders became models for carcinogenesis, revealing a fundamental principle of cancer biology. This insight transformed care. Modern management of XP includes early genetic diagnosis, rigorous cancer surveillance, chemoprevention and multidisciplinary support. Patients are no longer defined by isolation, but by proactive protection and counselling. The history XP illustrates dermatology’s unique contribution to molecular medicine. A rare childhood condition reframed ultraviolet radiation as a mutagen and the skin as a site of genomic vulnerability. XP demonstrates how careful attention to cutaneous disease can uncover mechanisms that reshape all of medicine, marking one of dermatology’s clearest transitions from descriptive specialty to molecular science.